series-a
Stage
1
Investors
About
Stoke Therapeutics is a clinical-stage biotechnology company developing genetic medicines that increase protein production from healthy genes by modulating RNA splicing using antisense oligonucleotides, targeting rare genetic diseases such as Dravet syndrome and autosomal dominant optic atrophy.
Explore Stoke Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.